A total of 140 patients were studied under controlled trial, all suffering from Lymphomas. 60 of these patients suffered from Non-Hodgkin's extranodal lymphoma (Group A) and 80 patients suffered from nodal Hodgkin's lymphoma (Group B). All of these patients were transfused with Lymphocyte specific killer stem cells which were modified from hemopoeitic stem cells of umbilical cord. As post stem cell booster Imatinib 400 mg od plus Pazopanib 400 mg od combination was used in Group A and in Group B Ibrutinib 140 mg bd was used as post stem cell booster. Blood Complete Picture done at 10 days post stem cell showed marked improvement in lymphocyte count in both groups. By the end of 1 month hemoglobin and platelets both started improving also. By end of 2 months the blood complete picture showed normal studies as per hemoglobin, platelets and lymphocyte counts. The treatment continued for 6 months and PET scans done at 7 months post stem cell showed clear scan for Group A. PET scan for Group B became clear by 8 months.
Lymphocyte specific killer stem cells modified from pleuripotent hemopoeitic umbilical cord stem cells are curative for treatment of all kinds of lymphomas.